Tuesday, 9 October 2018

Questions (220)

Michael McGrath

Question:

220. Deputy Michael McGrath asked the Minister for Health the steps he is taking to ensure that the drug Spinraza is made available to persons of spinal muscular atrophy; and if he will make a statement on the matter. [40610/18]

View answer

Written answers (Question to Health)

The HSE has statutory responsibility for medicine pricing and reimbursement decisions, in accordance with the Health (Pricing and Supply of Medical Goods) Act 2013. The Act specifies the criteria for decisions on the reimbursement of medicines. As Minister for Health, I do not have any statutory power or function in relation to reimbursement of medicines.

For a medicine to be considered for reimbursement by the HSE, it must first have a marketing authorisation from the European Medicines Agency (EMA) or the Health Products Regulatory Authority (HPRA), before being assessed under the 2013 Act.

HSE decisions on which medicines are reimbursed by the taxpayer are made on objective, scientific and economic grounds, on the advice of the National Centre for Pharmacoeconomics (NCPE). The NCPE conducts health technology assessments (HTAs) for the HSE, and makes recommendations on reimbursement to assist HSE decisions.

The NCPE uses a decision framework to systematically assess whether a drug is cost-effective as a health intervention. This process ensures that only treatments that are clinical and cost effective are reimbursed.

The HSE strives to reach a decision in as timely a manner as possible. However, because of the significant monies involved, it must ensure that the best price is achieved, as these commitments are often multi-million euro investments on an on-going basis. This can lead to a protracted deliberation process.

Nusinersen (Spinraza) is indicated for the treatment of 5q spinal muscular atrophy (SMA), a disorder characterised by progressive muscle atrophy and weakness.

In May 2017, the EMA granted market authorisation for nusinersen and in October 2017, the HSE received a reimbursement application for nusinersen.

In December 2017, the NCPE completed a HTA of nusinersen and did not recommend reimbursement at the price submitted. No decision has been arrived as yet on the application for the reimbursement of nusinersen as the statutory process is still on-going.